LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Diagnostic Test Detects Mycobacterium Tuberculosis with 96% Accuracy

By LabMedica International staff writers
Posted on 11 Jul 2012
Print article
A new assay is 96 % accurate in detecting rifampin-resistant Mycobacterium tuberculosis (TB). The assay is currently under development to provide rapid diagnosis and drug susceptibility information for TB.

A privately held molecular diagnostics company developing sample-to-result solutions, Great Basin Corporation (Salt Lake City, UT, USA) developed the new assay.

The technology entails an integrated disposable cartridge containing all necessary reagents and an inexpensive bench-top analyzer that executes the assay, interprets the results, and provides eye-visible detection to the clinician. The test is being automated in a manner consistent with the World Health Organization's (WHO; Geneva, Switzerland) ASSURED (Affordable, Sensitive, Specific, User-friendly, Rapid and Robust, Equipment-free, and Deliverable to end-users) goals for developing world point-of-care testing for drug-resistant TB.

More than 9.8 million cases of multidrug-resistant Mycobacterium tuberculosis (MDR TB) are reported worldwide each year, and more than half of those previously treated experience repeat infections. TB can be treated effectively if properly identified; however, mistreated or left untreated, can cause drug resistance and can be deadly. The poor sensitivity of diagnostic tests appears to be the main reason for delay of TB treatment.

A study of the new TB assay appeared in the July 2012 edition of the Journal of Clinical Microbiology. Authors of the study include scientists from Great Basin Corp. and from the Public Health Research Institute Tuberculosis Center, University of Medicine and Dentistry of New Jersey (Newark, NJ, USA).

"The need for improved point-of-care testing for drug resistance in MDR TB is acute, especially in the developing world," said Robert Jenison, CTO of Great Basin Corporation and study coauthor. "A significant advantage of the TB ID/R assay is that more information can be added to it to detect additional TB resistance mechanisms, potentially allowing for diagnosis of MDR-TB, even extremely drug-resistant TB (XDR-TB). This diagnostic capability can improve management and treatment for greater numbers of infected patients, further reducing transmission risks."

Related Links:

Great Basin Corporation
World Health Organization
Public Health Research Institute Tuberculosis Center, University of Medicine and Dentistry


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more